CN1066147C - 嘌呤衍生物及其制备方法 - Google Patents

嘌呤衍生物及其制备方法 Download PDF

Info

Publication number
CN1066147C
CN1066147C CN96198457.0A CN96198457A CN1066147C CN 1066147 C CN1066147 C CN 1066147C CN 96198457 A CN96198457 A CN 96198457A CN 1066147 C CN1066147 C CN 1066147C
Authority
CN
China
Prior art keywords
amino
carbamoyl
phenyl
ethyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN96198457.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN1202896A (zh
Inventor
J·齐默曼
H－G·凯普拉洛
P·伊姆巴克
P·福里特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1202896A publication Critical patent/CN1202896A/zh
Application granted granted Critical
Publication of CN1066147C publication Critical patent/CN1066147C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN96198457.0A 1995-11-01 1996-10-22 嘌呤衍生物及其制备方法 Expired - Fee Related CN1066147C (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CH3094/1995 1995-11-01
CH3094/95 1995-11-01
CH309495 1995-11-01
CH2213/96 1996-09-10
CH2213/1996 1996-09-10
CH221396 1996-09-10
PCT/EP1996/004573 WO1997016452A1 (en) 1995-11-01 1996-10-22 Purine derivatives and processes for their preparation

Publications (2)

Publication Number Publication Date
CN1202896A CN1202896A (zh) 1998-12-23
CN1066147C true CN1066147C (zh) 2001-05-23

Family

ID=25689809

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96198457.0A Expired - Fee Related CN1066147C (zh) 1995-11-01 1996-10-22 嘌呤衍生物及其制备方法

Country Status (13)

Country Link
US (1) US7091346B1 (enExample)
EP (1) EP0874846B1 (enExample)
JP (2) JP4004066B2 (enExample)
CN (1) CN1066147C (enExample)
AR (1) AR004134A1 (enExample)
AT (1) ATE236161T1 (enExample)
AU (1) AU7296896A (enExample)
BR (1) BR9611157A (enExample)
CA (1) CA2234609C (enExample)
DE (1) DE69627195T2 (enExample)
ES (1) ES2196181T3 (enExample)
PT (1) PT874846E (enExample)
WO (1) WO1997016452A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
US6794390B2 (en) * 1996-08-02 2004-09-21 Cv Therapeutics, Inc. Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha
WO1998016528A1 (en) 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
WO1999007705A1 (en) * 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases
US6573044B1 (en) 1997-08-07 2003-06-03 The Regents Of The University Of California Methods of using chemical libraries to search for new kinase inhibitors
CN1158269C (zh) 1997-10-27 2004-07-21 阿古龙制药公司 作为cdk抑制剂的取代的4-氨基-噻唑-2-基化合物
AU1631699A (en) * 1997-12-18 1999-07-05 E.I. Du Pont De Nemours And Company Cyclohexylamine arthropodicides and fungicides
KR100568658B1 (ko) * 1998-02-26 2006-04-07 아벤티스 파마슈티칼스 인크 6,9-이치환 2-[트랜스-(4-아미노시클로헥실)아미노]퓨린
UA66840C2 (uk) * 1998-02-26 2004-06-15 Авентіс Фармасьютікалз Інк. 6,9-дизаміщені 2-[транс-(4-аміноциклогексил)аміно]пурини, фармацевтична композиція та способи лікування проліферативного розладу, попередження апоптозу нервових клітин, захисту нервових клітин від руйнування
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6642231B2 (en) * 1998-02-26 2003-11-04 Aventis Pharmaceuticals Inc. 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
FR2793794B1 (fr) * 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
US20030187261A1 (en) * 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
WO2001082967A1 (fr) * 2000-04-28 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Compositions medicinales destinees a supprimer la production de ?-amyloide
US6861524B2 (en) 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
EP1399446B1 (en) * 2001-06-27 2005-08-03 Cyclacel Limited 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders
CZ294535B6 (cs) * 2001-08-02 2005-01-12 Ústav Experimentální Botaniky Avčr Heterocyklické sloučeniny na bázi N6-substituovaného adeninu, způsoby jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující
EP2258371A1 (en) 2001-08-10 2010-12-08 Novartis AG Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia
CA2463563A1 (en) * 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
GB0219052D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
KR20050072090A (ko) * 2002-09-19 2005-07-08 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 피라졸로피리딘
AU2003301407B2 (en) * 2002-10-15 2010-04-22 Irm Llc Compositions and methods for inducing osteogenesis
EP1608631A4 (en) 2003-03-28 2008-08-20 Scios Inc BICYCLIC PYRIMIDININHIBITORS OF TGF BETA
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
EP1960372B1 (en) 2005-12-15 2015-12-09 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
JP5208123B2 (ja) * 2006-12-08 2013-06-12 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
EA019941B1 (ru) 2006-12-08 2014-07-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
JP5703432B2 (ja) * 2007-03-28 2015-04-22 ノイロサーチ アクティーゼルスカブ プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用
EP2142546B1 (en) 2007-03-28 2017-06-07 Saniona A/S Purinyl derivatives and their use as potassium channel modulators
CZ302225B6 (cs) * 2007-07-04 2010-12-29 Univerzita Palackého v Olomouci Substituované 6-anilinopurinové deriváty jako inhibitory cytokinin oxidasy a prípravky obsahující tyto slouceniny
AU2009233964B2 (en) * 2008-04-07 2012-06-07 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2010034706A1 (en) * 2008-09-26 2010-04-01 Neurosearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
US8268838B2 (en) 2008-09-26 2012-09-18 Neurosearch A/S Substituted purinyl-pyrazole derivatives and their use as potassium channel modulators
US10952415B2 (en) 2011-03-09 2021-03-23 Richard G. Pestell Prostate cancer cell lines, gene signatures and uses thereof
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
HK1209673A1 (en) 2012-05-14 2016-04-08 Prostagene Llc Using modulators of ccr5 for treating cancer
EP2885290B1 (en) 2012-06-26 2017-10-18 Saniona A/S A phenyl triazole derivative and its use for modulating the gabaa receptor complex
EP2979708A1 (en) * 2013-03-27 2016-02-03 The Asan Foundation Composition for treatment or metastasis suppression of cancers which includes p34 expression inhibitor or activity inhibitor as active ingredient
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
CN122465832A (zh) 2014-07-30 2026-07-28 耶达研究及发展有限公司 用于培养多能干细胞的培养基
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (zh) * 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP4086257A1 (en) * 2016-09-30 2022-11-09 SRI International Dual clk/cdk1 inhibitors for cancer treatment
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
IL285083B1 (en) 2019-01-23 2026-06-01 Yeda Res & Dev Medium for pluripotent stem cells
CN120289460A (zh) * 2024-01-09 2025-07-11 中国科学院合肥物质科学研究院 含有嘌呤环的化合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0212535A1 (de) * 1985-08-17 1987-03-04 Roche Diagnostics GmbH N6-Disubstituierte Purinderivate, Verfahren zu deren Herstellung sowie diese Verbindungen enthaltende Arzneimittel

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR910700253A (ko) * 1989-01-31 1991-03-14 로버트 제이, 바란 N_6-치환-9-메틸아데닌: 신규한 부류의 아데노신 수용체 길항질
ATE178335T1 (de) * 1992-01-06 1999-04-15 Wellcome Found Therapeutische nukleoside der 2',3'-dideoxy-3'- fluor -purin reihe
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US5753635A (en) 1996-08-16 1998-05-19 Berlex Laboratories, Inc. Purine derivatives and their use as anti-coagulants
WO1998016528A1 (en) 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
CA2463563A1 (en) * 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
AU2003301407B2 (en) * 2002-10-15 2010-04-22 Irm Llc Compositions and methods for inducing osteogenesis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0212535A1 (de) * 1985-08-17 1987-03-04 Roche Diagnostics GmbH N6-Disubstituierte Purinderivate, Verfahren zu deren Herstellung sowie diese Verbindungen enthaltende Arzneimittel

Also Published As

Publication number Publication date
ES2196181T3 (es) 2003-12-16
AU7296896A (en) 1997-05-22
BR9611157A (pt) 1999-03-30
WO1997016452A1 (en) 1997-05-09
EP0874846A1 (en) 1998-11-04
CA2234609A1 (en) 1997-05-09
EP0874846B1 (en) 2003-04-02
JPH11514336A (ja) 1999-12-07
CN1202896A (zh) 1998-12-23
AR004134A1 (es) 1998-09-30
JP4004066B2 (ja) 2007-11-07
PT874846E (pt) 2003-08-29
US7091346B1 (en) 2006-08-15
HK1016580A1 (en) 1999-11-05
CA2234609C (en) 2006-11-28
JP2007231023A (ja) 2007-09-13
DE69627195T2 (de) 2004-01-29
DE69627195D1 (de) 2003-05-08
ATE236161T1 (de) 2003-04-15

Similar Documents

Publication Publication Date Title
CN1202896A (zh) 嘌呤衍生物及其制备方法
CN1047776C (zh) 具有药理学活性的吡啶类衍生物及其制备方法
US6083953A (en) 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative
TW434242B (en) 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
JP2000516626A (ja) 置換ピロロピリミジンおよびその製造方法
US5543414A (en) Achiral amino acid acyl esters of ganciclovir and its derivatives
CN1069643C (zh) 抑制巨细胞病毒的二氮杂萘及其类似物
JP2010507581A (ja) ＰＫＣ−θ阻害薬としてのプリン類
WO2008143674A1 (en) Purinones and 1h-imidazopyridinones as pkc-theta inhibitors
CN105153122A (zh) [(吲哚-3-基)嘧啶-2-基]氨基苯基丙-2-烯酰胺衍生物及盐、制备方法、应用
CN113717245B (zh) 含有2,8,9-三取代-9h-嘌呤结构片段的egfr降解剂及其盐和应用
WO1997023482A1 (en) 2,7-substituted octahydro-pyrrolo[1,2-a]pyrazine derivatives
EP2403839A2 (en) Neurotrophin mimetics and uses thereof
CN1067885A (zh) 2-氨基嘧啶-4-甲酰胺衍生物及其制法和医疗应用
JPH10501526A (ja) 多薬物耐性に対する作用物質としてのカルバゾール誘導体
JPH10501527A (ja) 多重薬剤耐性細胞を抗腫瘍剤に対して感受性にするためのインドロカルバゾール誘導体
JPH10500394A (ja) 多重薬剤耐性細胞を抗腫瘍剤に対して感受性にするための多環式ラクタム誘導体
CN101801975A (zh) 作为g蛋白抑制剂的吡唑并-吡嗪衍生物
HK1016580B (en) Purine derivatives and processes for their preparation
JPH0834789A (ja) ピロロインドールカルボン酸エステル誘導体及びその製造方法
JPH0834788A (ja) ピロロベンゾカルバゾール誘導体及びその製造方法
JPH0834786A (ja) トリフルオロメチルピロロインドール誘導体及びその製造方法
JPH0834787A (ja) ピロロカルバゾール誘導体及びその製造方法
HK1012339B (en) 2-(2-amino-1, 6-dihydro-6-oxo-purin-9-yl)methoxy-1, 3-propanediol derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20010523

Termination date: 20091123